IDBS partnered with Alchemi to accelerate AI-driven biopharma regulatory filings by connecting agentic workflows to Polar, IDBS’s governed data platform. The collaboration targets a long-running bottleneck: CMC teams assembling reports, reconstructing process histories, and preserving audit trails. The partnership aims to keep validated data traceable and auditable by drafting components of regulatory submissions—such as CMC technical reports, clinical study reports, and submission dossiers—through human-in-the-loop review. Alchemi said documents of this type have been produced up to 70% faster in customer deployments. Both companies framed the value as time savings without breaking compliance chains, aligning AI “agents” with data created and contextualized within Polar across the drug development lifecycle.